The invention is directed to compounds of Formula I, described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF.sub.1 antagonists and are useful in the treatment of disorders and diseases associated with CRF.sub.1 receptors, including CNS-related disorders and diseases.

 
Web www.patentalert.com

< Use of alpha-2 adrenergic receptor agonists

< (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma

> Quinazoline protein tyrosine phosphatase inhibitors

> Heterocyclic compounds as inhibitors of factor VIIa
~ 00288